Basiliximab for IL-2-Associated Inflammatory Disorder With Atopic Dermatitis

Sarah L Becker; Liza Kenny; Alison Small

doi:10.1111/pde.15913

Basiliximab for IL-2-Associated Inflammatory Disorder With Atopic Dermatitis

Pediatr Dermatol. 2025 Feb 25. doi: 10.1111/pde.15913. Online ahead of print.

Authors

Sarah L Becker¹, Liza Kenny¹, Alison Small¹

Affiliation

¹ Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.

PMID: 40000115
DOI: 10.1111/pde.15913

Abstract

Options for pediatric patients with severe atopic dermatitis who do not respond to biologics remain limited. We report the case of a 10-year-old boy with severe, recalcitrant atopic dermatitis associated with episodic fever, joint pains, and elevated serum IL-2R, which responded to basiliximab. To our knowledge, this is the first reported use of basiliximab for atopic dermatitis in a pediatric patient. This case highlights the potential for basiliximab as a therapy for severe cases of atopic dermatitis and the potential for precision medicine in dermatology.

Keywords: IL‐2R inhibitors; atopic dermatitis; autoinflammatory syndrome; basiliximab; monoclonal antibody; precision medicine.

Publication types

Case Reports